Study of PAX5-negative Hodgkin-like lymphomas
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at a rare type of lymphoma that looks like Hodgkin lymphoma but lacks a protein called PAX5. The goal is to better understand and diagnose this condition, which can be hard to tell apart from other lymphomas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with a type of lymphoma called classic Hodgkin lymphoma that does not have the PAX5 protein.
- Or you must have a lymphoma that is hard to tell apart from classic Hodgkin lymphoma without PAX5 and another type called ALK-negative anaplastic large T-cell lymphoma.
- You must be an adult (18 years or older).
- Your doctors must have results from molecular or genetic tests available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study enrolls adults with Hodgkin or non-Hodgkin lymphoma who plan to receive chemotherapy aimed at cure. It may help doctors better understand outcomes and how lymphoma care is managed over time.
This study looks at samples of tissue removed during routine procedures to better understand Hodgkin’s disease and non-Hodgkin’s lymphoma. It may help researchers learn more about what these cancers look like in tissue.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This study collects leftover tissue samples from patients with or without lymphoma to help researchers better understand lymph system cancers. It may be an option if you are already having a biopsy or surgery.
This trial is looking at new ways to predict how Hodgkin lymphoma will respond to treatment. It collects blood and tumor samples at key times to see if these can help doctors make better treatment decisions in the future.
This trial tests the safety of a new drug, CX-5461 (Pidnarulex), in people with certain types of aggressive B-cell lymphoma that have specific MYC gene changes. It aims to find out if this drug can help when standard treatments are no longer working.
Hear when a new Hodgkin or Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.